

ICYMI: HGF urges food developers to assess formulation IP before publishing results
Food developers risk overlooking patentable formulation work and losing protection through premature disclosure, according to HGF specialists speaking during PPTI’s webinar on foods for healthy aging.
• Formulation improvements may offer protectable inventions.
• Early records and disclosure checks help preserve options.
• Partners should agree ownership before exchanging samples and data.
“Formulation teams often undersell their work,” says Kerry Rees, Partner & Patent Attorney at HGF. He identifies improvements in stability, bitterness, solubility, texture and sedimentation as examples that may warrant assessment when they solve a technical problem in a new and non-obvious way.
Rees and HGF Patent Director Andrew Tindall joined representatives from Verley, Meala Foodtech and BMC Ingredients for Designing Foods for Healthy Aging: The Next Generation of Nutrition, hosted by PPTI in partnership with HGF on November 12.
Their advice begins before a company files an application. Rees recommends recording experiments, formulations, process changes and results, including unsuccessful work that could later provide useful comparisons. An invention log can also help establish who contributed and when.
Those records preserve options while a business determines its product, customers and market. Rees cautions against filing large numbers of applications without first understanding how the protection will support the company’s commercial plans.
Tindall says an existing ingredient may still offer opportunities for protection through a new formulation, manufacturing method or specific use. The evidence and wording required depend on what the company has developed and the benefit it seeks to protect.
“You don’t need clinical trial data to file a patent,” he says. “You just need enough evidence to make the benefit believable on the day you file.”
He describes measurable results from cell or animal models as possible early evidence, depending on the claim being pursued. Broad outcomes such as longer lifespan can take decades to establish, while a narrower effect may be investigated much sooner.
Waiting for additional data can strengthen support, but it also gives competitors time to file or publish. Tindall recommends considering filing once there is a concrete, measurable result that supports the proposed claims, with experiments designed to generate useful evidence from the outset.
Publication requires particular care. Rees warns that disclosing an invention before filing can undermine novelty in Europe. A conference presentation, paper, technical document or product announcement should be checked against existing applications before release.
An earlier filing may cover only the initial results. Later improvements and new data may need a separate assessment, while disclosure can also compromise information a company intended to retain as a trade secret.
Rees recommends combining patents with confidentiality where appropriate. Features competitors can identify from a product may favor patent protection; information that can genuinely remain undisclosed may be more suitable for trade-secret protection. Maintaining secrecy requires records and control over access and disclosure.
Co-development creates another set of decisions. Tindall recommends agreeing terms before samples or technical data change hands, including identifying the intellectual property each party brings and deciding how newly created work will be owned and used.
He gives a hypothetical example involving an ingredient supplier and a drinks manufacturer developing a stable ready-to-drink product. Both could contribute to the invention, making ownership and future use difficult to resolve without an agreement.
The arrangement might allocate ownership of a particular formulation to the manufacturer while preserving the supplier’s production technology and rights to other applications. The appropriate agreement depends on who funds the work, how each party benefits and the intended business model.
Investors also need an understandable account of the protection. Tindall says companies should explain how their IP relates to the product, who owns it and how the strategy will support future development. A large portfolio alone does not answer those questions.
His closing recommendation is to involve patent specialists while experiments can still be adjusted. Too often, he says, the discussion arrives after researchers have completed work that could have provided stronger support with a different experimental design. “Have that conversation early,” he says.
Watch Designing Foods for Healthy Aging: The Next Generation of Nutrition
If you liked this, check these out...
• Verley secures first US patent for dairy protein microparticulation technology
• Verley raises US$38 million Series A to take precision-fermented whey global as dairy strains under demand
• BMC Ingredients study finds ergothioneine and spermidine in Rhiza mycelium
If you have any questions or would like to get in touch with us, please email info@futureofproteinproduction.com
Heading
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
More News
SIGN-UP TO OUR NEWSLETTER
View the full newsletter archive at PPTI News







_main.jpg)